Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer

International Journal of Cancer

Volumn 61, Issue 5, 1995, Pages 597-600

  Duggan, C ^a   Maguire, T ^a   McDermott, E ^a   O'Higgins, N ^a   Fennelly, J J ^a   Duffy, M J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; RECEPTOR; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; HUMAN; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATORS; PROGNOSIS; RECEPTORS, CELL SURFACE; TIME FACTORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0029065722     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.2910610502     Document Type: Article

References (28)

1. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue
2. Prognostic value of urokinase plasminogen activator (uPA) and plasminogen activator inhibitors PAI‐1 and PAI‐2 in breast carcinomas
3. Prevention of metastasis by inhibition of the urokinase receptor
4. Human urokinase‐receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels
5. Urokinase‐type plasminogen activator and malignancy
6. Estradiol receptors in human breast carcinomas assayed by use of monoclonal antibodies
7. Urokinase plasminogen activator as a prognostic marker in different sub‐groups of patients with breast cancer
8. Urokinase‐plasminogen activator, a new and independent prognostic marker in breast cancer
9. The urokinase receptor and the regulation of cell‐surface plasminogen activation
10. Prognostic value of urokinase‐type plasminogen activator in 671 primary‐breast‐cancer patients
11. Relationship between cathepsin D, urokinase and plasminogen activator inhibitors in malignant vs. benign breast tumours
12. Urokinase receptor and colorectal‐cancer survival
13. Urokinase‐type plasminogen activator (u‐PA) is a predictor of early relapse in breast cancer
14. Urokinase (u‐PA) and its inhibitor PAI‐1 are strong and independent prognostic factors in node‐negative breast cancer
15. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers
16. Tissue plasminogen activators in breast cancer
17. Modulation of the in vitro invasion of human glioblastoma cells by urokinase‐type plasminogen‐activator‐receptor antibody
18. Binding of urokinase to specific receptor sites on human breast‐cancer membranes
19. Enzyme‐linked immunosorbent assay of cerbB‐2 oncoprotein in breast cancer
20. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell‐surface‐bound urokinase
21. Prognostic impact of urokinase, urokinase receptor and type of plasminogen activator inhibitor in squamous‐ and large‐cell lung‐cancer tissue
22. Asymptoticaly efficient rank invariant procedures
23. Receptor for urokinase is present in tumor‐associated macrophages in ductal breast carcinoma
24. Urokinase‐type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas
25. Examination of the role of the urokinase receptor in human colon‐cancer‐mediated laminin degradation
26. Multiparametric prognostic evaluation of biological factors in primary breast cancer
27. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cellsin vitro
28. r‐55,000 form of the human plasminogen activator, urokinase